6 important and encouraging new developments to watch out for
What's the skinny on C4 Therapeutics and other TPD programs at AACR and ASCO?
5 key and novel early areas of development which stood out to us at AACR22
Going beyond both G12C and G12D to a plethora of new targets and combination approaches
Just because a pathway has been called undruggable doesn't always mean it will be so!
Hot topics to follow at AACR22
Some important new research which may stimulate a whole new class of anti-cancer therapies
The battle over AR antagonists and degraders rages on as new clinical data emerge
It's time for an update on novel protein degraders
The intriguing science behind a novel protein degrader platform
What to watch out for in 2022
A look at some cool science and novel strategies for tackling an intractable target
It's time to tackle some intractable targets in oncology and elsewhere...
Update on C4, Kymera, Novartis and Vividion
New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.
Who's going to win in the battle between protein degraders and small molecule inhibitors?
What can we learn from C4 Therapeutics monoDAC, CFT7455?
A look at the subtleties and nuances under the hood of the Arvinas PROTACs
13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?
Emerging areas in cool new science around targeted therapies
Capturing attention in the crowded protein degradation niche
What to watch out for in the protein degradation niche
Getting to the centre of things with protein degradation
A rock around the myeloma clock through the eyes of a KOL - what stood out and what did not?
A critical look at the early stage BMS oncology pipeline
What's worth following on the targeted therapy front in breast cancer? A look pipelines and new indications from SABCS
A look at Kymera's protein degrader pipeline
Which hematology products in development produced the best data at ASCO 2020? We took a look at the key studies in lymphomas and myelomas to find out.
There are a few new developments of note to consider from ESMO Breast this weekend plus more to come at ASCO20 on Friday
An in-depth look at the emerging SERD landscape in ER+ metastatic breast cancer
What do we learn from the initial data with novel PROTAC technology?
Highlights and lowlights from Day 1 of JPM20
A look at off Broadway abstracts on early new product development and scientific findings of interest
How do we go about therapeutically targeting deep protein-protein interactions that can cause aberrant cancer activity? Here's one novel approach in early development...